ReParris Launches to Pioneer Regenerative Therapies for Age-Related Diseases, Addressing a $7 Trillion Healthcare Crisis

Company Seeks to Redefine Aging as a Treatable Condition and Calls for Regulatory Reform to Accelerate Access to Breakthrough Therapies

LOS ANGELES, March 11, 2025 /PRNewswire/ -- The economic burden of age-related diseases is projected to surpass $7 trillion by 2050, driven by rising rates of Alzheimer's, cardiovascular disease, cancer and metabolic disorders. Addressing this challenge, ReParris ("the Company"), a newly launched regenerative medicine company, aims to treat aging as a biological process, rather than an inevitability, by developing novel small-molecule therapies targeting inflammation-driven degeneration.

Founded by R. Rex Parris, JD, Mayor of Lancaster, Calif., and Denis Evseenko, MD, PhD, Professor of Orthopaedic Surgery, Stem Cell Research and Regenerative Medicine at USC, ReParris is harnessing the body's natural repair mechanisms to slow, halt and even reverse age-related disease progression.

"Our current approach to aging is reactive, costly and unsustainable," said Dr. Evseenko, an expert in stem cell biology and molecular pharmacology. "ReParris is advancing first-in-class small molecules designed to regenerate damaged tissues, modulate chronic inflammation and extend functional healthspan. The goal is not just to live longer, but to ensure that added years are healthy, productive and disease-free."

ReParris's therapeutic focus is based on decades of research identifying inflammation as the primary driver of age-related diseases. Key areas of development include:

• Pulmonary fibrosis – a progressive, fatal lung disease affecting 3 million people globally, with no cure and a median survival rate of three to five years post-diagnosis.
• Fatal complications of sepsis in elderly people – a leading cause of hospital deaths, with over 11 million fatalities annually, often triggered by immune system failure linked to aging. The COVID-19 pandemic further exacerbated these complications, increasing vulnerability and mortality rates among older individuals.
• Canine aging as a model for human longevity – dogs experience age-related diseases in a compressed timeframe, making them a powerful translational model for human longevity interventions. This program could accelerate clinical insights and de-risk future human trials.

The longevity biotechnology market is projected to reach $600 billion by 2030, driven by rapid advances in cellular rejuvenation, regenerative medicine and AI-driven drug development. ReParris leverages over a decade of translational research from USC, ensuring a strong foundation of scientific validation. The Company is exploring non-dilutive funding opportunities and strategic partnerships to accelerate development while minimizing investor risk.

"Medical innovation must outpace regulatory stagnation," added Mayor Parris, a longtime advocate for disruptive healthcare models. "The newly appointed HHS Secretary, Robert F. Kennedy, Jr., has an opportunity to modernize regulatory frameworks and expand access to investigational treatments for terminally ill patients. The United States must remain the global leader in longevity biotechnology, ensuring that life-extending treatments reach those in need."

ReParris is advocating for an expanded regulatory framework that allows age-related therapies to qualify for Expedited Access Pathways, similar to oncology drug approvals. The Company is actively engaging with industry and regulatory leaders to position its therapies for early-stage patient access.

About ReParris
ReParris is a regenerative medicine company developing novel small-molecule therapies to treat and prevent age-related diseases. Founded by Mayor R. Rex Parris, JD, and Dr. Denis Evseenko, MD, PhD, ReParris is dedicated to advancing treatments that target the biological mechanisms of aging. The Company's work prioritizes inflammation-driven conditions, including pulmonary fibrosis and sepsis, as well as longevity studies in canines, with the goal of extending and improving patients' lives. Positioned at the forefront of the longevity biotech revolution, ReParris is committed to providing accessible, lifesaving therapies to all patients in need.

SOURCE ReParris